Please assess the completion status of the following clinical trial:

Trial Title: Avalglucosidase Alfa Extension Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~Participants with Pompe disease who previously completed an avalglucosidase study.~The participant and/or their parent/legal guardian is willing and able to provide signed informed consent, and the participant, if \<18 years of age, was willing to provide assent if deemed able to do so.~The participant (and participant's legal guardian if participant is \<18 years of age) must have had the ability to comply with the clinical protocol.~The participant, if female and of childbearing potential, had to have a negative pregnancy test \[urine beta-human chorionic gonadotropin\] at baseline.~Exclusion criteria:~The participant was concurrently participating in another clinical study using investigational treatment.~The participant, in the opinion of the Investigator, was unable to adhere to the requirements of the study.~The participant had clinically significant organic disease (with the exception of symptoms relating to Pompe disease), including clinically significant cardiovascular, hepatic, pulmonary, neurologic, or renal disease, or other medical condition, serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, precluded participation in the study or potentially decreases survival.~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Avalglucosidase Alfa (Type: EXPERIMENTAL): administered intravenously every 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).